Company: LIMN
Filing Date: 2025-04-30
Form Type: 8-K12B
Source: 0001104659-25-042489
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-04-30
Form: 8-K12B
Chunk 2
---
IMN’s common stock and warrants
are deemed registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, by operation of paragraph (a) of Rule 12g-3
thereunder. LIMN hereby reports the succession in accordance with Rule 12g-3(f) under the Exchange Act, on Form 8-K using the EDGAR format
type 8-K12B, as notice that LIMN has become a successor issuer to IRAA pursuant to Rule 12g-3(a) under the Exchange Act.

A copy of the joint press release is furnished
as Exhibit 99.1 to this Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

Exhibit Index

| Exhibit 
 No.     
 99.1    |     | Description                                                               
 Joint Press Release, dated April 30, 2025.                                | ​ 
 ​ |
|:--------|:----|:--------------------------------------------------------------------------|:--|
| 104     |     | Cover Page Interactive Data File (embedded with the Inline XBRL document) |   |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: April 30, 2025 |                        |                         |
|:---------------------|:-----------------------|:------------------------|
|                      | LIMINATUS PHARMA, INC. |                         |
|                      | By:                    | /s/ Chris Kim           |
|                      | Name:                  | Chris Kim               |
|                      | Title:                 | Chief Executive Officer |